Please login to the form below

Not currently logged in
Email:
Password:

Potenza Therapeutics

This page shows the latest Potenza Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Astellas extends phase III programme for Rydapt rival gilteritinib

Astellas extends phase III programme for Rydapt rival gilteritinib

Oncology is a key priority for Astellas, and along with the Ganymed buy, it signed a wide-ranging immuno-oncology deal with Potenza Therapeutics last year, and followed it up with ... a $300m licensing deal with Immunomic Therapeutics.

Latest news

  • Astellas buys Ganymed to boost immuno-oncology pipeline Astellas buys Ganymed to boost immuno-oncology pipeline

    Last year it signed a wide-ranging immuno-oncology deal with Potenza Therapeutics and followed it up with a $300m licensing deal with Immunomic Therapeutics.

  • Astellas signs up to immuno-oncology deal Astellas signs up to immuno-oncology deal

    Astellas Pharma has signed a new and exclusive R&D deal with biotech firm Potenza Therapeutics in the growing new area of immuno-oncology. ... First generation immuno-oncology therapeutics have demonstrated meaningful clinical benefit to patients with

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CAN advertising

Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics